Australia markets closed

GeNeuro SA (GNRRF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.55000.0000 (0.00%)
At close: 09:33AM EST

GeNeuro SA

3 chemin du PrE-Fleuri
Plan-les-Ouates 1228
Switzerland
41 22 552 48 00
https://www.geneuro.com

Sector(s)
Industry
Full-time employees17

Key executives

NameTitlePayExercisedYear born
Mr. Jesus Martin-GarciaChairman & CEO711.84kN/A1962
Mr. Miguel PayróChief Financial OfficerN/AN/A1965
Dr. Hervé PerronChief Scientific OfficerN/AN/A1959
Dr. David Leppert M.D.Chief Medical OfficerN/AN/A1958
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Corporate governance

GeNeuro SA’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.